Tenax Therapeutics Inc
TENX
查看详细走势图
12.730USD
+0.370+2.99%
收盘 02/06, 16:00（美东）报价延迟15分钟
75.20M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.99%
5天
+1.76%
1月
-2.97%
6月
+115.40%
今年开始到现在
+4.43%
1年
+76.07%
查看详细走势图
TradingKey Tenax Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Tenax Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名43/392位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价25.25。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Tenax Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Tenax Therapeutics Inc亮点
亮点风险
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值低估
公司最新PE估值-17.13，处于3年历史低位
机构加仓
最新机构持股6.62M股，环比增加23.20%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值255.66K
分析师目标
根据
5
位分析师
强力买入
评级
25.250
目标均价
+92.31%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Tenax Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Tenax Therapeutics Inc简介
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
公司代码TENX
公司Tenax Therapeutics Inc
CEOGiordano (Christopher T)
网址http://www.tenaxthera.com/
相关品种
